CSF3 and neutropenia: Our findings, although limited by their retrospective nature, are broadly consistent with expert recommendations, which emphasize personalized G-CSF and antiemetic strategies, close monitoring for neutropenia in high-risk patients, and the need for further prospective evidence to refine supportive care in SG-treated TNBC [6].